Gevo, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Gevo, Inc. (Nasdaq: GEVO) on January 5, 2026, reporting events occurring on January 1, 2026, and January 5, 2026. The filing details significant executive leadership transitions, including the retirement of the President and Chief Operating Officer, the appointment of a successor, and the execution of new employment agreements for the President and Chief Financial Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements and personnel changes.
Material Changes and Executive Actions
- Retirement of Christopher M. Ryan: Dr. Ryan, President and Chief Operating Officer, announced his retirement effective on or about June 5, 2026. He will receive retirement amounts as defined in his existing employment agreement.
- Appointment of Greg Hanselman: Mr. Hanselman was hired as Executive Vice President, Operations and Engineering, and is expected to succeed Dr. Ryan as Chief Operating Officer in June 2026.
- Succession of CEO: Paul Bloom, currently President, is scheduled to succeed Patrick R. Gruber as Chief Executive Officer upon Dr. Gruber's retirement on or about April 1, 2026.
- New Employment Agreements: On January 1, 2026, the Company entered into an amended and restated agreement with Dr. Bloom and a new agreement with Oluwagbemileke (Leke) Agiri, Chief Financial Officer.
Compensation and Contractual Terms
| Executive | Role | Base Salary | Target Bonus | Severance (Without Cause/Good Reason) | Change in Control Severance |
|---|---|---|---|---|---|
| Paul Bloom | President (future CEO) | $550,000 | 100% of base | 6 months base + 18 months COBRA | 12 months base + 1.0x target bonus |
| Leke Agiri | Chief Financial Officer | $380,000 | 65% of base | 12 months COBRA (No cash severance unless CIC) | 12 months base + 1.0x target bonus |
Restrictive Covenants: Both executives are subject to non-compete, non-solicitation of clients, and non-solicitation of employees covenants. The non-compete period is 18 months for Dr. Bloom and 12 months for Mr. Agiri (reduced to 6 months if termination occurs during the Change in Control Protection Period). In consideration for these covenants, the Company granted 10,000 shares of restricted stock to each executive and agreed to non-compete payments upon termination for reasons other than cause, death, or disability.
Outlook and Risks
The filing outlines a structured transition plan to ensure operational continuity. Key risks include the potential disruption of operations during the leadership transition period between January and June 2026. The agreements define "cause" and "good reason" strictly, limiting executive ability to claim severance without meeting specific criteria such as material salary reduction or material breach by the Company.
Investor Verification Checklist
- Verify the exact retirement date of Patrick R. Gruber (CEO) and Christopher M. Ryan (COO) to confirm the timeline for leadership changes.
- Review the attached Exhibits 10.1 and 10.2 for full legal text of the employment agreements.
- Monitor the press release (Exhibit 99.1) for additional context on the strategic rationale for these changes.
- Confirm the vesting schedule of the 10,000 restricted stock shares granted to Dr. Bloom and Mr. Agiri.
- Assess the impact of the non-compete payments on future cash flow if either executive departs.